MétaCan
Menu
Back to cohort

Abstract 10627: Benefits of Icosapent Ethyl in Patients with Prior Peripheral Artery Disease: REDUCE-IT PAD

2021· article· en· W3217392123 on OpenAlexaff
Deepak L. Bhatt, Philippe Gabríel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Jean‐Claude Tardif, Steven Ketchum, Rebecca A. Juliano, Lisa Jiao, Christina Copland, Ralph T. Doyle, Christie M. Ballantyne

Bibliographic record

VenueCirculation · 2021
Typearticle
Languageen
FieldMedicine
TopicPeripheral Artery Disease Management
Canadian institutionsMontreal Heart Institute
Fundersnot available
KeywordsMedicineClinical endpointMyocardial infarctionPlaceboStroke (engine)Internal medicineNumber needed to treatUnstable anginaCoronary artery diseaseRevascularizationAnginaCardiologySurgeryRelative riskConfidence intervalRandomized controlled trialPathology

Abstract

fetched live from OpenAlex

Introduction: REDUCE-IT found significant benefit in 8179 statin-treated patients randomized to icosapent ethyl (IPE). Whether that benefit extends to patients with peripheral artery disease (PAD) was unknown. Methods: The primary endpoint was time to cardiovascular (CV) death, myocardial infarction (MI), stroke, coronary revascularization, or hospitalization for unstable angina. The key secondary endpoint was CV death, MI, or stroke. Total (first plus recurrent) events were also assessed. PAD was an inclusion criterion in the established CV disease cohort. Prespecified and post hoc analyses by baseline history of PAD history were performed. Results: Of 5785 (70.7%) REDUCE-IT patients enrolled with established CV disease, 688 had PAD. IPE demonstrated statistically similar risk reduction in first (interaction P [p int ]=0.58) and total (p int =0.78) primary endpoints in patients with established CV disease with or without PAD, though PAD patients had higher first (placebo: 32.8% with vs 24.5% without PAD) and total (placebo: 162.3 vs 101.7 per 1000 patient-years) event rates. The primary endpoint event rate with PAD was 26.2% with IPE vs 32.8% with placebo (HR 0.78; 95% CI 0.59, 1.03; P=0.08) and total events were 112.8 per 1000 patient-years with IPE vs 162.3 with placebo (RR 0.68; 95% CI 0.48, 0.95; P=0.03) (Figure). Primary endpoint absolute risk reductions (ARR) and numbers needed to treat (NNT) suggest benefit for patients with (ARR 6.6%; NNT 15) and without (6.1%; 16) PAD. Safety did not differ substantially by PAD history and was generally consistent with the overall study. Conclusions: In REDUCE-IT, patients with PAD were at very high risk of subsequent ischemic events. IPE provided consistent CV benefit in patients with or without PAD.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.019
Threshold uncertainty score0.557

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.017
GPT teacher head0.252
Teacher spread0.235 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations9
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueCirculationSame topicPeripheral Artery Disease ManagementFrench-language works237,207